Last updated: February 23, 2026
What is the drug associated with NDC 66689-0406?
The NDC 66689-0406 corresponds to Vymeda (vilazodone) tablets. Vilazodone is an antidepressant approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD). It functions as a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at 5-HT1A receptors.
What is the market landscape for vilazodone?
Market Size and Growth
- Global antidepressant market was valued at approximately USD 17.5 billion in 2022.
- Expected compound annual growth rate (CAGR): 2.9% from 2023 to 2030 (Grand View Research).
- US accounted for roughly 45% of the global market in 2022.
Key competitors
| Drug Name |
Class |
Market Share (2022) |
FDA Approval Year |
Pricing (Wholesale) |
| Prozac (fluoxetine) |
SSRI |
20% |
1987 |
USD 0.10 per 20 mg |
| Zoloft (sertraline) |
SSRI |
18% |
1991 |
USD 0.12 per 50 mg |
| Lexapro (escitalopram) |
SSRI |
12% |
2002 |
USD 0.15 per 10 mg |
| Vilazodone |
SSRI + 5-HT1A partial agonist |
5% (market penetration) |
2011 |
USD 7.50 per 10 mg |
Current market position
Vilazodone holds a smaller market share compared to older SSRIs, facing competition on pricing and clinician familiarity. It is prescribed mainly for patients who do not respond to or tolerate other SSRIs.
What pricing trends are projected?
Current Price
- Wholesale acquisition cost (WAC): ~$7.50 per 10 mg tablet (as per Red Book, 2023).
- Average retail price: About USD 830 per month for a typical 30-day supply (based on current retail pharmacy data).
Price projections (2023-2030)
| Year |
Expected Wholesale Price (USD) |
Rationale |
| 2023 |
USD 7.50 per 10 mg |
Current levels |
| 2025 |
USD 7.80 per 10 mg |
Slight inflation, supply stability |
| 2028 |
USD 8.20 per 10 mg |
Potential patent exclusivity, inflation |
| 2030 |
USD 8.50 per 10 mg |
Market stabilization, slight inflation |
Key factors influencing price trends
- Patent Status: Vilazodone was approved in 2011; patent expiry could lead to generics around 2031-2033.
- Generic Competition: Entry expected between 2028-2030, likely lowering prices by 20-50%.
- Market Penetration: Increased adoption in treatment-resistant depression may support steadier pricing.
- Insurance Coverage: Reimbursement rates could influence net prices for providers.
What is the outlook for market growth?
- Prescription volume growth is projected at 3-4% annually, driven by increased awareness of depression treatment options.
- Generics will erode branded market share, lowering average prices.
Key Opportunities and Risks
Opportunities
- New formulations (e.g., extended-release) could command higher prices.
- Expanding indications (e.g., anxiety disorders) could increase patient volume.
- Differentiation through improved safety or efficacy profiles.
Risks
- Rapid generic entry depresses prices.
- Competitor innovations in depression therapeutics.
- Changes in reimbursement policies.
Summary: Market and Price Trajectory
| Year |
Price (USD per 10 mg) |
Prescription Volume Growth |
Market Penetration |
| 2023 |
USD 7.50 |
3% annually |
Current baseline |
| 2025 |
USD 7.80 |
3.5% |
Moderate growth |
| 2028 |
USD 8.20 |
4% (post-patent expiry) |
Increasing competition |
| 2030 |
USD 8.50 |
4.5% |
Industry-wide expansion |
Key Takeaways
- Vilazodone remains a niche option within the antidepressant market, with limited market share.
- Pricing is stable but will decline once generics enter the market, expected around 2028-2030.
- Market growth hinges on expanding indications and clinician adoption.
- Competitive pressures from established SSRIs and new therapies threaten long-term pricing power.
- Diversification into formulations and indications represents strategic opportunities.
FAQs
Q1. When will generic vilazodone likely enter the market?
A1. Predicted around 2028-2030, roughly 17-19 years post-approval, based on patent expiration timelines.
Q2. How will generic entry affect market pricing?
A2. Expect price reductions of 20-50%, leading to narrower profit margins for branded formulations.
Q3. Are there new formulations of vilazodone in development?
A3. Currently, no major pipeline formulations are publicly disclosed, but extended-release versions could influence future pricing.
Q4. What is the main therapeutic advantage of vilazodone?
A4. Its dual mechanism as an SSRI and 5-HT1A partial agonist may offer faster onset and reduced sexual side effects.
Q5. How does vilazodone compare in efficacy to other SSRIs and SNRIs?
A5. Clinical trials demonstrate comparable efficacy to other SSRIs, with some evidence suggesting improved tolerability in certain populations.
References
- Grand View Research. (2022). Antidepressant Market Size, Share & Trends Analysis Report.
- U.S. Food and Drug Administration. (2011). FDA Approval for Vilazodone.
- Red Book. (2023). Wholesale Acquisition Cost Data.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement and Pricing Data.
- MarketWatch. (2023). Antidepressant Market Trends and Predictions.
[1] APA citation style for all sources used.
